EU project IMMIDIET warns: control hypertension in Europe

An EU-funded population study has shown that hypertension, an important risk factor for cardiovascular disease, is a serious problem in Europe. The results of the IMMIDIET project indicate that high blood pressure has become more common in Italy than in England or Belgium, a reversal of the commonly accepted trend. They also demonstrate that awareness is quite limited, and that those who are diagnosed do not adequately manage their condition. The results have been published online in the Journal of Hypertension.

The IMMIDIET project ('Dietary habit profile in European communities with different risk of myocardial infarction: the impact of migration as a model of gene/environment interaction') was funded by the European Union under the 'Quality of life and management of living resources' Thematic Programme of the Fifth Framework Programme (FP5). The current study was carried out by researchers in Italy, Belgium, the Netherlands, France and the UK.

The IMMIDIET researchers, working closely with general practitioners in southwest London in England, Limburg in Belgium and Abruzzo in Italy, examined 1,604 patients. The patients underwent a comprehensive medical examination that included blood pressure measurement, and were asked to fill in a questionnaire about their lifestyle and perception of health status. They defined 'hypertension' as systolic blood pressure of at least 140mmHg or diastolic blood pressure of at least 90mmHg, or 'current antihypertensive treatment'.

The researchers were mindful of the effects of both genetic and lifestyle factors on cardiovascular disease, and recruited both married couples formed by people from the same area (Italians married with Italians in the Abruzzo region, and so forth) and mixed-nationality couples in different phases of the project.

Their findings showed, surprisingly, that high blood pressure was less common in England than in Belgium or Italy. This regional difference represents a reversal of the so-called north-south 'cardiovascular gradient'.

"This inversion is surprising," said Dr Licia Iacoviello of Italy's Catholic University of Campobasso. "It may reflect the ongoing changes of lifestyle habits. Paradoxically, northern European countries, where cardiovascular risk was higher than in Italy, are now modifying their habits, getting closer to the ancient Italian food and lifestyle culture, thus living a healthier life. [However], in Italy traditional habits are being lost, and we may be observing the negative effects on health."

Overall, the study found that awareness of hypertension was poor: 24% of study participants were hypertensive and 56% of these were unaware of their condition (one third was receiving treatment). Among those who had been diagnosed with high blood pressure, less than half had managed to bring down their blood pressure to acceptable levels.

According to Professor Francesco Cappuccio of the University of Warwick in the UK, "All national healthcare systems should do more to help control hypertension. Although in England the management of high blood pressure is better as compared to some other countries, in part due to the incentives that general practitioners receive to achieve blood pressure targets, we still have too many patients not adequately treated and the incidence of hypertension is rising still."

The IMMIDIET study also found that awareness of cardiovascular disease, hypertension in particular, is higher in women than in men. Also, women were more likely to be under treatment for hypertension, and were more successful in bringing down their blood pressure to internationally accepted 'desirable' levels. The researchers attributed this 'more successful management' to the increased willingness of women to participate in the healthcare system.

Dr Iacoviello warned, "Looking at these data and at other studies conducted in recent years, we fear Europe is facing a dangerous situation. Hypertension is a critical causative factor for serious diseases like heart attack and stroke, but it is still grossly underestimated. So we need urgent and intensive initiatives in this field, introducing new and effective strategies in controlling this threat."

Professor Cappuccio added, "This is a call for an integrated action not only on better management of hypertension but on the implementation of widespread strategies for the prevention of it in the first place."

For further information, please visit:
http://www2.warwick.ac.uk/fac/med/research/csri/cvme/immidiet

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...